Bone Biologics Corp (BBLG): Price and Financial Metrics
GET POWR RATINGS... FREE!
BBLG Stock Price Chart Interactive Chart >
BBLG Price/Volume Stats
|Current price||$1.30||52-week high||$7.12|
|Prev. close||$1.22||52-week low||$1.13|
|Day high||$1.30||Avg. volume||755,415|
|50-day MA||$1.57||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||13.46M|
Bone Biologics Corp (BBLG) Company Bio
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Most Popular Stories View All
BBLG Latest News Stream
|Loading, please wait...|
BBLG Latest Social Stream
View Full BBLG Social Stream
Latest BBLG News From Around the Web
Below are the latest news stories about Bone Biologics Corp that investors may wish to consider to help them evaluate BBLG as an investment opportunity.
Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!
Huadi International Group (HUDI) -16%.Bone Biologics (BBLG) -12%.Reviva Pharmaceuticals (RVPH) -10%.Pacific Biosciences of California PACB -9% after reports lower than expected prelim
Welcome back, trader!
Today, investors in Bone Biologics and BBLG stock are seeing some serious gains as investors dive into niche small caps.
Newly listed Bone Biologics Corporation (NASDAQ: BBLG ) shares are surging after the Company announced to present at the H.C. Wainwright BioConnect Virtual Conference. Bone Biologics is focused on regenerative medicine for bone. The Company is working on the Nell-1 protein, a bone graft substitute product on bone regeneration in spinal fusion, and has rights to trauma and osteoporosis applications. Recombinant NELL-1 is purified and mixed Full story available on Benzinga.com
BBLG Price Returns